Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes
In this exploratory study, 12 weeks of empagliflozin treatment lowered cardiac filling pressures, but without the anticipated reflex increase in sympathetic nervous activity.
Authors
- David M. Kaye (ORCID: https://orcid.org/0000-0003-4058-0372)
- Agus Salim (ORCID: https://orcid.org/0000-0003-3999-7701)
- Murray Esler (ORCID: https://orcid.org/0000-0002-8755-7658)
- Anne T. Reutens (ORCID: https://orcid.org/0000-0003-1650-0205)
- Jonathan E. Shaw (ORCID: https://orcid.org/0000-0002-6187-2203)
- Mark Emmanuel Cooper (ORCID: https://orcid.org/0000-0001-7785-2488)
- Dulari Hakamuwa Lekamlage
Institutions
- Baker Heart and Diabetes Institute (AU)
- The Alfred Hospital (AU)
- Monash University (AU)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102304
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29